Why carry out this study?

Sodium-glucose cotransporter 2 (SGLT2) inhibitors promote urinary glucose excretion.

The differences in the effects of various SGLT2 inhibitors are unknown.

Flash glucose monitoring (FGM) was used to identify the differences in efficacy between tofogliflozin and ipragliflozin treatments.

What was learned from the study?

Data collected using FGM demonstrated that tofogliflozin was more effective and safer than ipragliflozin in reducing diurnal glycemic variability and lowering the risk of nocturnal hypoglycemia.

The risk of cardiovascular disease was higher in patients with advanced renal dysfunction; it is unclear whether SGLT2 inhibitors can reduce the risk of cardiovascular diseases in such patients.